Last updated on August 2020

A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer


Brief description of study

This study will evaluate the efficacy and safety of intravenous RC48-ADC in patients with locally advanced or metastatic HER2 overexpressed biliary tract cancer who have failed first-line chemotherapy.

Clinical Study Identifier: NCT04329429

Find a site near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.